4YWP image
Entry Detail
PDB ID:
4YWP
Keywords:
Title:
Sucrose Binding Site in genetically engineered Carbonic anhydrase IX
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2015-03-20
Release Date:
2015-10-14
Method Details:
Experimental Method:
Resolution:
1.45 Å
R-Value Free:
0.18
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Carbonic anhydrase 2
Mutations:A65S, N67Q, E69T, I91L, F131V, K170E, L204A
Chain IDs:A
Chain Length:257
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Peptide-like Molecules
PRD_900003
Primary Citation
A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX.
Acta Crystallogr F Struct Biol Commun 71 1352 1358 (2015)
PMID: 26457530 DOI: 10.1107/S2053230X1501239X

Abstact

Human carbonic anhydrase (CA; EC 4.2.1.1) isoform IX (CA IX) is an extracellular zinc metalloenzyme that catalyzes the reversible hydration of CO2 to HCO3(-), thereby playing a role in pH regulation. The majority of normal functioning cells exhibit low-level expression of CA IX. However, in cancer cells CA IX is upregulated as a consequence of a metabolic transition known as the Warburg effect. The upregulation of CA IX for cancer progression has drawn interest in it being a potential therapeutic target. CA IX is a transmembrane protein, and its purification, yield and crystallization have proven challenging to structure-based drug design, whereas the closely related cytosolic soluble isoform CA II can be expressed and crystallized with ease. Therefore, we have utilized structural alignments and site-directed mutagenesis to engineer a CA II that mimics the active site of CA IX. In this paper, the X-ray crystal structure of this CA IX mimic in complex with sucrose is presented and has been refined to a resolution of 1.5 Å, an Rcryst of 18.0% and an Rfree of 21.2%. The binding of sucrose at the entrance to the active site of the CA IX mimic, and not CA II, in a non-inhibitory mechanism provides a novel carbohydrate moiety binding site that could be further exploited to design isoform-specific inhibitors of CA IX.

Legend

Protein

Chemical

Disease

Primary Citation of related structures